Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Allogene Therapeutics, Inc.
ALLO
$1.65
Name : Allogene Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $570,059,968.00
EPSttm : -0.66
finviz dynamic chart for ALLO
Allogene Therapeutics, Inc.
$1.65
1.20%
$0.02
ALLO — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

24.92

Margin Of Safety %

Put/Call OI Ratio

0.09

EPS Next Q Diff

-0.01

EPS Last/This Y

0.28

EPS This/Next Y

-0.07

Price

1.66

Target Price

8.75

Analyst Recom

1.27

Performance Q

-22.54

Upside

-627.9%

Beta

0.55

Ticker: ALLO




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-08-28ALLO2.010.500.1014590
2026-08-31ALLO1.980.481.6514908
2026-09-02ALLO1.980.550.1615668
2026-09-03ALLO1.980.541.1615795
2026-09-04ALLO1.970.580.1016153
2026-09-08ALLO1.8550.570.0116397
2026-09-09ALLO1.720.550.2516671
2026-09-10ALLO1.7650.580.0116978
2026-09-11ALLO1.7850.570.0017260
2026-09-14ALLO1.7850.540.0217909
2026-09-15ALLO1.7250.540.3617930
2026-09-16ALLO1.6750.540.0017972
2026-09-17ALLO1.7250.260.0216836
2026-09-18ALLO1.6850.250.0716940
2026-09-21ALLO1.6850.100.3713196
2026-09-22ALLO1.710.100.0113151
2026-09-23ALLO1.6750.100.0013236
2026-09-24ALLO1.660.100.0013357
2026-09-25ALLO1.6550.090.1513651
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-08-28ALLO2.0225.9- -0.59
2026-08-31ALLO1.9925.9- -0.59
2026-09-01ALLO1.9925.9- -0.59
2026-09-02ALLO1.9725.9- -0.59
2026-09-03ALLO1.9925.9- -0.59
2026-09-04ALLO1.9725.9- -0.59
2026-09-08ALLO1.8525.9- -0.59
2026-09-09ALLO1.7225.9- -0.59
2026-09-10ALLO1.7625.9- -0.59
2026-09-11ALLO1.7825.9- -0.59
2026-09-14ALLO1.7825.9- -0.59
2026-09-15ALLO1.7325.9- -0.59
2026-09-16ALLO1.7325.9- -0.59
2026-09-17ALLO1.7325.9- -0.59
2026-09-18ALLO1.6825.9- -0.59
2026-09-21ALLO1.6925.9- -0.59
2026-09-22ALLO1.7125.9- -0.59
2026-09-23ALLO1.6825.9- -0.59
2026-09-24ALLO1.6625.9- -0.59
2026-09-25ALLO1.6625.9- -0.59
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-08-28ALLO-0.1052.0724.67
2026-08-31ALLO-0.1053.5124.67
2026-09-01ALLO-0.1053.5124.67
2026-09-02ALLO-0.1053.5124.66
2026-09-03ALLO-0.1053.5124.66
2026-09-04ALLO-0.1053.5124.66
2026-09-08ALLO-0.0953.8524.66
2026-09-09ALLO-0.0953.8524.66
2026-09-10ALLO-0.0953.8524.65
2026-09-11ALLO-0.0953.8524.72
2026-09-14ALLO-0.0953.8424.72
2026-09-15ALLO-0.0953.8424.72
2026-09-16ALLO-0.0953.8424.72
2026-09-17ALLO-0.0953.8424.72
2026-09-18ALLO-0.0953.8424.72
2026-09-21ALLO-0.0453.8424.72
2026-09-23ALLO-0.0453.8424.72
2026-09-24ALLO-0.0453.8424.72
2026-09-25ALLO-0.0453.8424.92
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS​

-0.13

Avg. EPS Est. Current Quarter

-0.14

Avg. EPS Est. Next Quarter

-0.14

Insider Transactions

-0.04

Institutional Transactions

53.84

Beta

0.55

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

27

Growth Score

31

Sentiment Score

30

Actual DrawDown %

93.7

Max Drawdown 5-Year %

-96.3

Target Price

8.75

P/E

Forward P/E

PEG

P/S

122.86

P/B

1.31

P/Free Cash Flow

EPS

-0.67

Average EPS Est. Cur. Y​

-0.59

EPS Next Y. (Est.)

-0.65

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-3566.68

Relative Volume

0.52

Return on Equity vs Sector %

-64.2

Return on Equity vs Industry %

-44.6

EPS 1 7Days Diff

EPS 1 30Days Diff

0.02

EBIT Estimation

◆ ALLO Healthcare
$1.65
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
10/20
Pullback
21/25
Volume
11/15
Valuation
12/20
TP/AR
2/10
Options
8/10
RSI
34.1
Range 1M
9.4%
Sup Dist
2.6%
🚀
Momentum Growth
Ride accelerating trends
N/A
34 /100
WEAK
Momentum
3/25
Growth
16/30
Estimates
1/20
Inst/Vol
6/15
Options
8/10
EPS Yr
30.9%
EPS NY
-5.7%
52W%
18%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +430.3% upside
Quality
3/30
Valuation
16/30
Growth
12/25
Stability
8/10
LT Trend
4/5
Upside
+430.3%
Quality
27
ALLO — P/E HistoricalBiotechnology
Allogene Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 150
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
ALLO

Latest News

—
Caricamento notizie per ALLO…
stock quote shares ALLO – Allogene Therapeutics, Inc. Stock Price stock today
news today ALLO – Allogene Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALLO – Allogene Therapeutics, Inc. yahoo finance google finance
stock history ALLO – Allogene Therapeutics, Inc. invest stock market
stock prices ALLO premarket after hours
ticker ALLO fair value insiders trading